Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramucirumab + FOLFOX4
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**ramucirumab + FOLFOX4** is a combination regimen consisting of **ramucirumab**, a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2), and **FOLFOX4**, a chemotherapy regimen composed of oxaliplatin, folinic acid (leucovorin), and fluorouracil (5-FU)[1][2][3]. Ramucirumab inhibits angiogenesis by blocking activation of VEGFR-2, decreasing tumor vascularization. FOLFOX4 acts through a cytotoxic effect, impairing DNA synthesis and function in rapidly dividing cells. This combination is studied as first-line therapy for advanced hepatocellular carcinoma; its tolerability is limited, but preliminary efficacy supports further investigation, with dose modification and careful patient selection recommended[1][3].
- Brand names
- ramucirumab + FOLFOX4
- Other names
- ramucirumab + FOLFOX4
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on ramucirumab + FOLFOX4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramucirumab + FOLFOX4.